HistoGeneX is now CellCarta Learn More

The Caprion-HistoGeneX team consists of industry veterans representing multiple sectors. Collectively, you will be working with a team who has pioneered global scientific and enterprise innovations and accomplishments.  We believe these perspectives and experience are vital contributors to the success of clinical development programs.

Martin LeBlanc Chief Executive Officer LI In Bug 300x255

Martin LeBlanc Headshot

A co-founder of Caprion, Martin has for over 15 years led Caprion’s technology development, laboratory operations and commercial strategy focused on specialized laboratory research services in the fields of proteomics, immune monitoring, and personalized medicine. Profitable and rapidly growing based on its research contracts and strategic partnerships with over 75 global pharmaceutical and biotechnology companies, Caprion is also developing its own proprietary diagnostics tests for cancer, diabetes, and infectious diseases. Since 2007, Martin has concluded 3 company acquisitions and has successively managed Caprion under the ownership of 3 leading healthcare private equity firms, including the recent sale of Caprion to GHO Capital in July 2017.

Prior to Caprion, Martin began his professional career as a management consultant with McKinsey & Company. He then initiated his career as a biotech entrepreneur at Advanced Bioconcept, initially as Vice-President of Sales & Marketing and then as General Manager following the company’s acquisition by NEN Life Sciences (now part of Perkin-Elmer). Martin is currently a member of the Board of Directors of Caprion, Softbox Systems, Mispro Biotech Services, Prevtec Microbia, Montreal InVivo, the Atlantic Cancer Research Institute and of the Centre for Commercialization of Cancer Immunotherapy. He is also a member of the Investment Committee of the Amorchem venture fund.

Martin earned his bachelor’s degree in Economics from the University of Moncton prior to completing an M.A. in Economics and Politics at Oxford University as a Rhodes Scholar.

Nick Wright, MBA President and Global Chief Operating Officer LI In Bug 300x255

Nick Wright

Nick brings nearly 30 years of global business experience in healthcare services and products, scientific products, medical devices, and distribution. Nick joined Caprion in October 2020 as the President and Global Chief Operating Officer responsible for Global Laboratory and Commercial Strategy as well as the Information Technology and Human Resources functions of the global corporation. He is also responsible for ensuring the company has the adequate structure and processes in place to provide a platform for future growth.

Prior to joining Caprion, Nick has worked extensively for Baxter Healthcare, Fisher Scientific (now Thermo Fisher Scientific), and Covance (CRO).  Having started his career in sales he has had roles of increasing responsibility in sales, marketing, business development, country management, regional general management, divisional operations and manufacturing, and global leadership.  Most recently he was the CEO & President of a privately held clinical trial research site network in the US.

Nick earned undergraduate BS & BA degrees from Northwestern University, and MBA from the Kellogg School of Management.

Anthony Mattacchione, MBA, CPA Global Chief Financial Officer LI In Bug 300x255

Tony Mattacchione

Tony is a seasoned financial executive with a proven background leading teams in a variety of business environments including strategic growth and operating model transformations, business acquisitions, and turnarounds.  He joined Caprion in October 2020 and oversees the finance, accounting, tax, treasury, and legal functions of the global corporation.

Prior to joining Caprion, Tony was Senior Vice President and CFO at Albany Molecular Research, Inc. – a GTCR/Carlyle Group portfolio CDMO. In this role, he had leadership responsibilities for all aspects of finance, accounting, tax, treasury, pricing, global information systems, lender relations, acquisitions/divestitures, and corporate strategy.  He also shared responsibility for several enterprise-wide projects. Prior to this, Tony served as CFO for Bruker Corporation, a publicly traded global scientific instrumentation provider.  He also held other finance executive roles with Merck KGaA, Millipore, and Gerber Scientific.  In addition to his corporate finance roles, he has also served as an auditor at Price Waterhouse.

Tony holds a BS in accounting from Central Connecticut State University, an MBA from the University of Connecticut, and is a CPA.

Todd Chermak, PHD Chief Regulatory and Government Affairs Officer LI In Bug 300x255

Todd Chermak

Todd joined Caprion in September 2020 as the leader of our quality, regulatory and government affairs team, overseeing the overall regulatory requirements on ISO, CAP /CLIA, GLP and GCLP, and assisting clients in defining their global regulatory pathways for their development and clinical programs.

Todd brings more than 26 years of combined experience in the biopharmaceutical, diagnostics, and food/nutrition businesses at Abbott.  Todd has held a variety of technical and leadership roles in R&D, Operations, QA, and Regulatory Affairs.  He has served on a number of boards and academic advisory positions including Regulatory Affairs Professional Society (RAPS), Lambs Farm, the International Life Sciences Institute, the Dean’s Advisory Board for the School of Pharmacy at Purdue University and as a Ford Scholar at Northwestern’s Kellogg School of Management.

Todd earned his bachelor’s degree in Pharmacy from Purdue University, a master’s degree in Engineering and Management Sciences from Northwestern University and a PhD in Pharmacy from the University of Illinois.

Mark Kockx, MD, PhD. Founder, Global Chief Medical & Scientific Officer


Dr. Mark Kockx founded HistoGenex Laboratories in 2001. At the University of Antwerp, Belgium, Dr. Kockx pioneered methodologies to elucidate apoptotic and cytostatic response of cancer patients after treatments with targeted therapies. His subsequent collaborations with global pharmaceutical companies led to the founding of Histogenex Laboratories.

Dr. Kockx is an internationally recognized pathologist-scientist who has operated on the forefront of personalized medicine developments. He continues to lead initiatives to standardize biomarker analysis practices in addition to adapting novel technologies. Dr. Kockx has been extensively involved with the clinical trials that led to the approval of well-known targeted therapies such as EGFR, BRAF and MEK inhibitors. His current passions are two fold. He is introducing practices and workflows for next generation IHC, combining innovations of multiplex staining, quantification and image capture. He has also developed an Immunomics program, a state of the art biomarker program that supports the evolving and numerous needs of immunotherapy development.

Dirk Hendriks, PharmD, PhD, Founder, Chief Financial Officer & Director Strategic Business Development


Dr. Dirk Hendriks is a co-founder of HistoGeneX. In addition to serving as the financial officer and directing the strategic business development at HistoGeneX, Dr. Hendriks is a clinical pathologist and professor of Medical Biochemistry at the University of Antwerp in Belgium. He maintains an active lecturing schedule covering medical biochemistry, clinical pathology and laboratory management courses. In his university group, prof. Hendriks studies the development of new fibrinolytic mechanisms and drugs for the treatment of thrombo-embolic diseases.

His business experience includes extensive deal-structuring collaborations with the pharmaceutical Industry and also with strategic vendors. Previously, Dr. Hendriks has also successfully founded clinical pathology laboratories in the Antwerp area with subsequent mergers and acquisition transactions of these entities.

 Christopher Ung, MSc, MBA. Chief Business Officer

CHRISTOPHER 1C1A0620Mr. Christopher Ung has served in the companion diagnostics field since its inception and is one of the original pioneers of the personalized medicine field. He led the global commercialization efforts of the HercepTest™ and pharmDx EGFR companion diagnostic assays and continues to lead and implement global biomarker strategies for drug development projects. He has established several global companion diagnostic partnerships that have played a pivotal role in targeted therapy development and has set up CAP, CLIA laboratories in the US, Scotland, China, and Singapore.

Mr. Ung leads the development and execution of HistoGeneX’s strategic and business initiatives, leveraging the company’s solid tumor and anatomic pathology services. Prior to joining HistoGeneX, he was Vice President of Strategic Business & Operations at Quintiles, Chief Operating Officer for Targeted Molecular Diagnostics and Chairman of the Pathology Business Group at DAKO.